Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.
Identifieur interne : 000A26 ( PubMed/Checkpoint ); précédent : 000A25; suivant : 000A27Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.
Auteurs : A. Faure [France] ; P. Leblanc-Veyrac ; N. El MassiouiSource :
- Neuroscience [ 1873-7544 ] ; 2010.
English descriptors
- KwdEn :
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (pharmacology), Animals, Behavior, Animal (drug effects), Conditioning, Operant (drug effects), Corpus Striatum (drug effects), Corpus Striatum (metabolism), Dopamine (metabolism), Dopamine Agonists (pharmacology), Extinction, Psychological (drug effects), Habits, Male, Oxidopamine, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (psychology), Quinpirole (pharmacology), Rats, Rats, Sprague-Dawley, Receptors, Dopamine D1 (agonists), Receptors, Dopamine D2 (agonists), Receptors, Dopamine D3 (agonists), Reward.
- MESH :
- chemical , agonists : Receptors, Dopamine D1, Receptors, Dopamine D2, Receptors, Dopamine D3.
- chemical , metabolism : Dopamine.
- chemical , pharmacology : 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine, Dopamine Agonists, Quinpirole.
- chemically induced : Parkinsonian Disorders.
- drug effects : Behavior, Animal, Conditioning, Operant, Corpus Striatum, Extinction, Psychological.
- metabolism : Corpus Striatum.
- psychology : Parkinsonian Disorders.
- Animals, Habits, Male, Oxidopamine, Rats, Rats, Sprague-Dawley, Reward.
Abstract
Dopamine (DA) deafferentation of the dorsolateral striatum has been shown to prevent habit development, leaving instrumental behavior under action-outcome control that is persistently sensitive to modification of the motivational value of the reward. The present experiment further explored the basis of this dysfunction by examining the ability of intrastriatal DA agonist injections (D1 SKF 38393 or D2/D3 Quinpirole) during overtraining of a signaled instrumental task to restore habit formation in rats subjected to bilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal dopaminergic pathway. Overtraining was followed by a test of goal sensitivity by satiety-specific devaluation of the reward. The results confirmed the impaired shift in performance from action to habit in control lesioned rats. However, lesioned rats repeatedly injected with quinpirole D2/D3 agonist showed an increase in non-rewarded instrumental responses (intertrials periods) during overtraining, suggesting the development of perseverative behavior. Following the procedure of devaluation, quinpirole D2/D3 agonist treatment, and to a lesser extent SKF 38393 D1 agonist, caused the persistence of sensitivity to reward devaluation, indicating clear goal-directed behavior despite extended training. This absence of restoration of habit formation by DA agonist treatment is discussed in the light of DA agonist effects in Parkinson patients.
DOI: 10.1016/j.neuroscience.2010.03.047
PubMed: 20362642
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:20362642Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.</title><author><name sortKey="Faure, A" sort="Faure, A" uniqKey="Faure A" first="A" last="Faure">A. Faure</name><affiliation wicri:level="3"><nlm:affiliation>CNRS, UMR 8195, Orsay, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS, UMR 8195, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Leblanc Veyrac, P" sort="Leblanc Veyrac, P" uniqKey="Leblanc Veyrac P" first="P" last="Leblanc-Veyrac">P. Leblanc-Veyrac</name></author><author><name sortKey="El Massioui, N" sort="El Massioui, N" uniqKey="El Massioui N" first="N" last="El Massioui">N. El Massioui</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20362642</idno><idno type="pmid">20362642</idno><idno type="doi">10.1016/j.neuroscience.2010.03.047</idno><idno type="wicri:Area/PubMed/Corpus">000A78</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A78</idno><idno type="wicri:Area/PubMed/Curation">000A38</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A38</idno><idno type="wicri:Area/PubMed/Checkpoint">000A38</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.</title><author><name sortKey="Faure, A" sort="Faure, A" uniqKey="Faure A" first="A" last="Faure">A. Faure</name><affiliation wicri:level="3"><nlm:affiliation>CNRS, UMR 8195, Orsay, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS, UMR 8195, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Leblanc Veyrac, P" sort="Leblanc Veyrac, P" uniqKey="Leblanc Veyrac P" first="P" last="Leblanc-Veyrac">P. Leblanc-Veyrac</name></author><author><name sortKey="El Massioui, N" sort="El Massioui, N" uniqKey="El Massioui N" first="N" last="El Massioui">N. El Massioui</name></author></analytic><series><title level="j">Neuroscience</title><idno type="eISSN">1873-7544</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (pharmacology)</term><term>Animals</term><term>Behavior, Animal (drug effects)</term><term>Conditioning, Operant (drug effects)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Dopamine (metabolism)</term><term>Dopamine Agonists (pharmacology)</term><term>Extinction, Psychological (drug effects)</term><term>Habits</term><term>Male</term><term>Oxidopamine</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (psychology)</term><term>Quinpirole (pharmacology)</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Receptors, Dopamine D1 (agonists)</term><term>Receptors, Dopamine D2 (agonists)</term><term>Receptors, Dopamine D3 (agonists)</term><term>Reward</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term><term>Receptors, Dopamine D3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine</term><term>Dopamine Agonists</term><term>Quinpirole</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term><term>Conditioning, Operant</term><term>Corpus Striatum</term><term>Extinction, Psychological</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Habits</term><term>Male</term><term>Oxidopamine</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Reward</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine (DA) deafferentation of the dorsolateral striatum has been shown to prevent habit development, leaving instrumental behavior under action-outcome control that is persistently sensitive to modification of the motivational value of the reward. The present experiment further explored the basis of this dysfunction by examining the ability of intrastriatal DA agonist injections (D1 SKF 38393 or D2/D3 Quinpirole) during overtraining of a signaled instrumental task to restore habit formation in rats subjected to bilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal dopaminergic pathway. Overtraining was followed by a test of goal sensitivity by satiety-specific devaluation of the reward. The results confirmed the impaired shift in performance from action to habit in control lesioned rats. However, lesioned rats repeatedly injected with quinpirole D2/D3 agonist showed an increase in non-rewarded instrumental responses (intertrials periods) during overtraining, suggesting the development of perseverative behavior. Following the procedure of devaluation, quinpirole D2/D3 agonist treatment, and to a lesser extent SKF 38393 D1 agonist, caused the persistence of sensitivity to reward devaluation, indicating clear goal-directed behavior despite extended training. This absence of restoration of habit formation by DA agonist treatment is discussed in the light of DA agonist effects in Parkinson patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20362642</PMID><DateCreated><Year>2010</Year><Month>05</Month><Day>18</Day></DateCreated><DateCompleted><Year>2010</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2014</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7544</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Neuroscience</Title><ISOAbbreviation>Neuroscience</ISOAbbreviation></Journal><ArticleTitle>Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.</ArticleTitle><Pagination><MedlinePgn>477-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuroscience.2010.03.047</ELocationID><Abstract><AbstractText>Dopamine (DA) deafferentation of the dorsolateral striatum has been shown to prevent habit development, leaving instrumental behavior under action-outcome control that is persistently sensitive to modification of the motivational value of the reward. The present experiment further explored the basis of this dysfunction by examining the ability of intrastriatal DA agonist injections (D1 SKF 38393 or D2/D3 Quinpirole) during overtraining of a signaled instrumental task to restore habit formation in rats subjected to bilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal dopaminergic pathway. Overtraining was followed by a test of goal sensitivity by satiety-specific devaluation of the reward. The results confirmed the impaired shift in performance from action to habit in control lesioned rats. However, lesioned rats repeatedly injected with quinpirole D2/D3 agonist showed an increase in non-rewarded instrumental responses (intertrials periods) during overtraining, suggesting the development of perseverative behavior. Following the procedure of devaluation, quinpirole D2/D3 agonist treatment, and to a lesser extent SKF 38393 D1 agonist, caused the persistence of sensitivity to reward devaluation, indicating clear goal-directed behavior despite extended training. This absence of restoration of habit formation by DA agonist treatment is discussed in the light of DA agonist effects in Parkinson patients.</AbstractText><CopyrightInformation>2010 IBRO. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faure</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CNRS, UMR 8195, Orsay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leblanc-Veyrac</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>El Massioui</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroscience</MedlineTA><NlmUniqueID>7605074</NlmUniqueID><ISSNLinking>0306-4522</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance></Chemical><Chemical><RegistryNumber>20OP60125T</RegistryNumber><NameOfSubstance UI="D019257">Quinpirole</NameOfSubstance></Chemical><Chemical><RegistryNumber>67287-49-4</RegistryNumber><NameOfSubstance UI="D015647">2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber><NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015647" MajorTopicYN="N">2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003216" MajorTopicYN="N">Conditioning, Operant</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005108" MajorTopicYN="N">Extinction, Psychological</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006184" MajorTopicYN="Y">Habits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019257" MajorTopicYN="N">Quinpirole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050637" MajorTopicYN="N">Receptors, Dopamine D3</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="N">Reward</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>12</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>03</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20362642</ArticleId><ArticleId IdType="pii">S0306-4522(10)00440-9</ArticleId><ArticleId IdType="doi">10.1016/j.neuroscience.2010.03.047</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><settlement><li>Orsay</li></settlement></list><tree><noCountry><name sortKey="El Massioui, N" sort="El Massioui, N" uniqKey="El Massioui N" first="N" last="El Massioui">N. El Massioui</name><name sortKey="Leblanc Veyrac, P" sort="Leblanc Veyrac, P" uniqKey="Leblanc Veyrac P" first="P" last="Leblanc-Veyrac">P. Leblanc-Veyrac</name></noCountry><country name="France"><noRegion><name sortKey="Faure, A" sort="Faure, A" uniqKey="Faure A" first="A" last="Faure">A. Faure</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000A26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:20362642
|texte= Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:20362642" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |